Form 8-K

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 8, 2012

 

 

Natus Medical Incorporated

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   000-33001   77-0154833

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

1501 Industrial Road, San Carlos, California 94070

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (650) 802-0400

Not applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


ITEM 5.07. Submission of Matters to a Vote of Security Holders

On June 8, 2012, Natus Medical Incorporated (the “Company”) held its annual meeting of stockholders. At this meeting, Doris E. Engibous and William M. Moore were both re-elected to serve on the Board of Directors for a three-year term until 2015. Additionally, shareholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2012, provided advisory approval of the Company’s executive compensation, and approved an amendment to the Company’s Revised and Restated Certificate of Incorporation.

 

     For      Against      Abstain      Broker
Non-Votes
 

Proposal 1: Election of Directors

           

Nominee:

           

Doris E. Engibous

     21,488,013         1,563,360         7,642         3,279,387   

William M. Moore

     16,766,514         6,284,859         7,642         3,279,387   

Proposal 2: Ratification of Deloitte & Touche LLP as Auditors

     25,540,831         92,217         705,354         —     

Proposal 3: Advisory Approval of the Company’s Executive Compensation

     21,156,254         1,862,122         40,639         3,279,387   

Proposal 4: Approval of Elimination of Supermajority Voting Thresholds

     22,703,411         344,563         11,041         3,279,387   

No other matters were considered or voted upon at the meeting.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  NATUS MEDICAL INCORPORATED
Date: June 12, 2012   By:  

/s/ Steven J. Murphy

    Steven J. Murphy
    Vice President Finance and Chief Financial Officer